Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials.
AbbVie Inc (NYSE: ABBV) saw its stock fall nearly 13% after reporting disappointing mid-stage trial results for emraclidine, ...
Asian stocks fell, following a record-setting day for U.S. stocks, as China’s stimulus package disappointed investor ...
AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials. Abbvie said the trials did not show a statistically significant ...
AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...
Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Related: Bristol Myers Squibb's stock jumps on schizophrenia-drug approval "While we are disappointed with the results, we are continuing to analyze the data to determine next steps," Roopal ...
Stocktwits on MSN3d
AbbVie Stock Declines After Schizophrenia Drug Trials Miss Mark, But Retail Stays StoicShares of pharma major AbbVie Inc ($ABBV) tumbled over 12% on Monday after the company disclosed that its Schizophrenia drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback